Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRRT with PARP inhibitor for advanced gastroenteropancreatic neuroendocrine tumors
NL-OMON60130Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2022
- Countries
- 1
01
Overview
Phase 1, single-arm trial in Gastroenteropancreatic Carcinoid Tumor, sponsored by Erasmus MC. Started Mar 2022; status: recruiting.
02
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON60130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60130.